Bulletin du cancer最新文献_第2页

What are the sociodemographic characteristics of lung cancer patients travelling far to get surgery? 肺癌患者远行手术的社会人口学特征是什么？

IF 0.8

Bulletin du cancer Pub Date : 2025-09-15 DOI: 10.1016/j.bulcan.2025.07.020

Alexandre Quillet, Nasreddine Khadraoui, Nicolas Isambert, Thomas Systchenko, Nolwenn Le Stang, Gautier Defossez

{"title":"What are the sociodemographic characteristics of lung cancer patients travelling far to get surgery?","authors":"Alexandre Quillet, Nasreddine Khadraoui, Nicolas Isambert, Thomas Systchenko, Nolwenn Le Stang, Gautier Defossez","doi":"10.1016/j.bulcan.2025.07.020","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.020","url":null,"abstract":"Background: Lung cancer remains a global public health challenge, with late-stage diagnosis limiting treatment options. Surgery is recommended for early-stage disease (I-IIIA) and can only be performed in authorized centres. The aim of this study is to provide a spatial description of access to surgery for lung cancer patients and to identify the sociodemographic characteristics of patients who are furthest from home for their treatment.Methods: A population-based study was conducted on patients diagnosed with non-small cell lung cancer (stages I-IIIA) between 2008 and 2020, identified from the Poitou-Charentes Cancer Registry (south-western France). The distance between the patient's home and the place of surgery was computed using geographic coordinates. A map of patient flows by department was produced. Logistic regression models were used to identify sociodemographic and tumour factors associated with distance to surgery (cut-off 100km). Sensitivity analyses were performed by varying the distance threshold (50, 150 and 200km).Results: Twenty-two percent of patients travelled more than 100km for surgery. This proportion was higher in Charente and Charente-Maritime (45% and 31% respectively) than in Deux-Sèvres and Vienne (9% and 2% respectively). Female sex and middle socioeconomic status were associated with a greater distance travelled for surgery. Sex was the only variable that remained significant for all thresholds studied.Conclusions: Sociodemographic factors including sex, place of residence and socioeconomic status are important determinants of distance travelled for lung cancer surgery. These findings allow better understanding of these patients' pathways taking into account regional specificities.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Access to anticancer drugs in Africa]. [在非洲获得抗癌药物]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-12 DOI: 10.1016/j.bulcan.2025.07.013

Tresor Sumbu, Mor Fall, Marina Yao, Tamba Bobo Yombouno, Bertrand Pourroy

{"title":"[Access to anticancer drugs in Africa].","authors":"Tresor Sumbu, Mor Fall, Marina Yao, Tamba Bobo Yombouno, Bertrand Pourroy","doi":"10.1016/j.bulcan.2025.07.013","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.013","url":null,"abstract":"Childhood cancer is rapidly increasing across the African continent, but survival rates remain significantly lower than in high-income countries due to structural and economic barriers. This review analyses the major challenges hindering access to pediatric cancer medicines in Africa and examines the initiatives implemented to address them. Three main obstacles are identified: the low availability of medicines, exacerbated by stockouts and the lack of local production; the high cost of treatments, limiting accessibility, especially in the absence of universal health coverage; and weaknesses in pharmaceutical governance, including inefficient supply chains and insufficient regulation. In response to these challenges, several initiatives are emerging. While emergency actions, such as the shipment of cancer medicines by organizations like the GFAOP, have helped meet urgent needs, they do not replace structural solutions. Sustainable improvement relies on the training of healthcare professionals, particularly pharmacists specialized in pediatric oncology - an area supported by the GFAOP through the MAEva program and the University Diploma in Clinical Oncology Pharmacy -, the integration of anticancer medicines into universal health coverage policies, and the strengthening of local production and pharmaceutical governance, notably through the African Medicines Agency. An integrated approach, combining local production, effective regulation, and specialized training, is essential to sustainably improve access to treatments and reduce inequalities in pediatric oncology care across Africa.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pembrolizumab with chemoradiotherapy in high risk locally advanced cervical cancer]. [派姆单抗联合放化疗治疗高危局部晚期宫颈癌]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-12 DOI: 10.1016/j.bulcan.2025.07.009

Mathilde Haberstich, Manuel Rodrigues

引用次数: 0

[Subcutaneous versus intravenous routes in oncology: Preferences and impacts for patients and healthcare professionals]. [肿瘤皮下与静脉途径：对患者和医疗保健专业人员的偏好和影响]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-11 DOI: 10.1016/j.bulcan.2025.07.018

Sarah Mir, Katia Desroziers, Sarah Saget, Alexandre Gherardi, Amandine Groenez, Julie Paolantonacci, Anne-Cécile Regin, Béchir Ben Hadj Yahia, Cyril Esnault, Christos Chouaid

{"title":"[Subcutaneous versus intravenous routes in oncology: Preferences and impacts for patients and healthcare professionals].","authors":"Sarah Mir, Katia Desroziers, Sarah Saget, Alexandre Gherardi, Amandine Groenez, Julie Paolantonacci, Anne-Cécile Regin, Béchir Ben Hadj Yahia, Cyril Esnault, Christos Chouaid","doi":"10.1016/j.bulcan.2025.07.018","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.018","url":null,"abstract":"Introduction: The introduction of subcutaneous formulation in oncology led to significant changes for patients and healthcare professionals, with under-explored organizational and economic impacts. The aim of this pragmatic literature review is to compile evidence documenting the impact of subcutaneous formulation in comparison with intravenous administration in oncology, on patients, healthcare professionals and health facilities, and the associated economic implications.Methods: The analysis is based on the PRISMA methodology to identify relevant articles and posters published or presented between 2017 and September 2023 in five major European countries, using keywords related to patients perspective, organizational impacts on health facilities, and economic impacts.Results: Among the 558 identified articles and communications, 16 met the inclusion and exclusion criteria. Between 69% and 99% of patients indicated a preference for the subcutaneous formulation mainly due to the timesaving benefits it allows. The duration of inpatient hospital stay was reduced by 33% to 68% for patients treated with trastuzumab. In France, optimized care pathways for subcutaneous administration of trastuzumab and rituximab increased economic benefits with an estimated average total gain of €157,103 per department.Discussion: This literature review highlights the significant benefits of using subcutaneous formulation versus intravenous formulation in oncology. Its usage is clearly favored by stakeholders, and it enables significant cost savings, further enhanced by the implementation of dedicated healthcare pathways.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors]. [了解生物学以确定卵巢颗粒细胞肿瘤化疗以外的新治疗靶点]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-09 DOI: 10.1016/j.bulcan.2025.07.017

Sil Endale Ahanda, Alexandra Lainé, Brunhilde Hanvic, Quentin Verdet, Léa Ikhlef, Antonella De Palma, Sarah Fieuws, Anthony Ferrari, Eric Cumunel, Nicolas Chopin, Christine Rousset-Jablonski, Léa Rossi, Pierre Meeus, Anne-Agathe Serre, Isabelle Treilleux, Isabelle Ray-Coquard, Olivia Le Saux

{"title":"[Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors].","authors":"Sil Endale Ahanda, Alexandra Lainé, Brunhilde Hanvic, Quentin Verdet, Léa Ikhlef, Antonella De Palma, Sarah Fieuws, Anthony Ferrari, Eric Cumunel, Nicolas Chopin, Christine Rousset-Jablonski, Léa Rossi, Pierre Meeus, Anne-Agathe Serre, Isabelle Treilleux, Isabelle Ray-Coquard, Olivia Le Saux","doi":"10.1016/j.bulcan.2025.07.017","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.017","url":null,"abstract":"Granulosa cell tumors (GCTs) are rare ovarian neoplasms, accounting for 2-5% of all ovarian cancers. Two histological types have been described: juvenile (JGCT) and adult (AGCT), the latter accounting for around 95% of the GCTs. AGCTs are mostly diagnosed at an early stage and commonly have a good prognosis. However, GCTs tend to be associated with late recurrence in about a third of cases which are a major concern. These recurrences often require repeated surgical interventions. Systemic treatments, for their part, show limited effectiveness in this context, highlighting the need to identify new therapeutic targets. Thus, better biological characterization of these tumors would enable us to propose more targeted treatments. To achieve this, the molecular characteristics of GCTs have been explored. Most AGCTs harbor a mutation in the FOXL2 transcription factor sequence, therefore allowing to investigate therapeutic perspectives targeting its signalling, as well as setting the first steps towards immunotherapy in these tumors. Knowledge of JGCTs is more limited due to their rarity. However, molecular analysis revealed that ∼60% of the JGCTs bore a genetic mutation in the AKT1 oncogene. However, its clinical significance has still to be explored. For both GCTs subtypes, the CDK4/6-Rb1 axis is promising. Consequently, exploring the molecular features and their role in the biology of these tumors could open up new avenues for targeted and personalized therapies, thereby improving patient care.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Oncologists and hematologists' perspective on advance directives. A French national survey]. 肿瘤学家和血液学家对预先指示的看法。[法国全国调查]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-08 DOI: 10.1016/j.bulcan.2025.06.009

Amélie Cambriel, Kevin Serey, Adrien Pollina-Bachellerie, Mathilde Cancel, Jacques-Olivier Bay, Carole Bouleuc, Jean-Pierre Lotz, Francois Philippart

{"title":"[Oncologists and hematologists' perspective on advance directives. A French national survey].","authors":"Amélie Cambriel, Kevin Serey, Adrien Pollina-Bachellerie, Mathilde Cancel, Jacques-Olivier Bay, Carole Bouleuc, Jean-Pierre Lotz, Francois Philippart","doi":"10.1016/j.bulcan.2025.06.009","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.06.009","url":null,"abstract":"Background: The prevalence of cancers and hematological malignancies is high and continues to grow. The severity of these pathologies calls for patients to be given the opportunity to express their values, particularly with regard to the intensity of treatment and the type of care they wish to receive. However, the prevalence of advance directives (ADs) in this population remains low. The aim of our study was to assess the perception of advance directives by French oncologists and hematologists, and their involvement in the promotion and use of these directives.Methods: Observational, cross-sectional study based on an online questionnaire sent to the population of interest.Results: Four hundred and ten oncologists (50.1%) and 318 haematologists (33.7%) completed the questionnaire. In total, 65.9% of oncologists and 68.9% of hematologists were attending physicians or equivalent. ADs were systematically or frequently offered to the patients by 38.4 and 30.7% of oncologists and hematologists, respectively. The main limitations to mentioning ADs were the fear of creating anxiety in patients (oncologists: 74.6% and hematologists: 64.4%) and the stability of the disease (32.9 and 54.1%). ADs were perceived as unhelpful or even dangerous by 24.9 and 27.4%. Finally, 68.5 and 67.3% considered that the trusted support person could be more relevant than ADs.Conclusion: The majority of hematologists and oncologists consider that ADs may be useful. However, only a third of practitioners mention them regularly. The main reason for avoiding discussions about ADs was the fear of creating anxiety.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Prevention and management of heavy uterine bleeding in pediatric patients treated for an acute leukemia: Guidelines of the SFCE leukemia committee]. [儿科急性白血病患者重度子宫出血的预防和处理：SFCE白血病委员会指南]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-05 DOI: 10.1016/j.bulcan.2025.07.007

Audrey Grain, Céline Falaise, Virginie Gandemer, Céline Khouri, Laura Olivier, Audrey Petit, Alexandre Theron, Charlotte Garczynski, Julia Vergier, Caroline Oudot, Vanessa Vautier

{"title":"[Prevention and management of heavy uterine bleeding in pediatric patients treated for an acute leukemia: Guidelines of the SFCE leukemia committee].","authors":"Audrey Grain, Céline Falaise, Virginie Gandemer, Céline Khouri, Laura Olivier, Audrey Petit, Alexandre Theron, Charlotte Garczynski, Julia Vergier, Caroline Oudot, Vanessa Vautier","doi":"10.1016/j.bulcan.2025.07.007","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.07.007","url":null,"abstract":"The harmonization workshops of the leukemia committee of the Société française des cancers de l'enfant (SFCE) aim to establish practical recommendations based on the one hand, on data from the literature and international recommendations and, on the other hand, by consensus in the absence of formally proven data. Adolescent pubescent girls and young adults undergoing intensive chemotherapy treatment may present with heavy uterine bleeding (HUB). Data collected from 25 French centers showed that there was considerable heterogeneity in the management of HUB either in prophylaxis or curative strategy. Analysis of the literature showed that, given the incidence of spontaneous amenorrhea during chemotherapy treatment, there is no indication for systematic prophylaxis of HUB in patients treated for leukemia. In case of proven HUB, non-hormonal treatment and hormonal treatment can be introduced as a matter of urgency. For secondary prophylaxis, various hormonal treatments aiming at achieving prophylactic amenorrhea may be discussed.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospects of the therapeutic approaches of ketogenic diet on the clinical outcomes of cancer: A scoping review. 生酮饮食治疗方法对癌症临床结果的展望：范围综述。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-05 DOI: 10.1016/j.bulcan.2025.05.012

Anmar Al-Taie, Jouwana Elmasri

{"title":"Prospects of the therapeutic approaches of ketogenic diet on the clinical outcomes of cancer: A scoping review.","authors":"Anmar Al-Taie, Jouwana Elmasri","doi":"10.1016/j.bulcan.2025.05.012","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.05.012","url":null,"abstract":"The scientific community has become more enthusiastic about ketogenic diet (KD) to improve the outcomes in medical conditions, including cancer by exploiting the reprogramed metabolism of cancer cells, making the diet a promising candidate as an adjuvant cancer therapy. From this perspective, the aim of this study was to provide a broad overview covering the therapeutic effects, evaluating the clinical evidence of clinical studies underlying the implementation of the KD in the context of cancer treatment and prognosis. A scoping literature search between the years 1990 and 2023 was carried out by using PRISMA guidelines and searching through different databases of the clinical studies supporting the effectiveness and benefits of KD in various carcinomas that could provide findings of evidence on the prognosis and clinical outcomes of cancer treatment. A total of 23 cancer-related publications were included, 12 of which focused on brain cancer particularly glioblastoma multiforme (GBM), 4 on both breast and ovarian cancers, and 3 on pancreatic cancer. A total of 10 publications were reported as clinical trials regarding cancers of the brain (4 studies), breast (2 studies), and ovarian (4 studies). Case report studies were reported in 3 publications for brain cancer, and 2 publications for breast cancer. Nearly almost of the studies found that there was a potential role of KD in the prognosis of cancer treatment. The current review suggests that cancer patients may get favorable effects from the implementation of KD to support clinical outcomes of cancer treatment.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)]. 急性移植物抗宿主病治疗：在类固醇和鲁索利替尼之后，哪一种三线治疗？(SFGM-TC)]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-05 DOI: 10.1016/j.bulcan.2025.05.014

Tereza Coman, Fabio Andreozzi, Jaques-Olivier Bay, Jérôme Cornillon, Thierry Guillaume, Fati Hamzy, Laetitia Souchet, Pascal Turlure, Ambroise Marçais, François Dachy, Yves Beguin, Claude Eric Bulabois, Sanae Daghri, Anne Huynh, Leonardo Magro, Yves Chalandon

{"title":"[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].","authors":"Tereza Coman, Fabio Andreozzi, Jaques-Olivier Bay, Jérôme Cornillon, Thierry Guillaume, Fati Hamzy, Laetitia Souchet, Pascal Turlure, Ambroise Marçais, François Dachy, Yves Beguin, Claude Eric Bulabois, Sanae Daghri, Anne Huynh, Leonardo Magro, Yves Chalandon","doi":"10.1016/j.bulcan.2025.05.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.05.014","url":null,"abstract":"Acute graft-versus-host disease (GVHDa) is one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT) patients. While the first-line consensus treatment has been based on systemic corticosteroid therapy for many years, ruxolitinib has recently been approved and has become the standard second-line treatment. Nevertheless, the effectiveness of ruxolitinib remains limited to 40 % of cortico-resistant patients, raising the crucial question of selecting a third-line treatment. Among the therapeutic modalities described, this workshop selected fecal microbiota transplantation (FMT), mesenchymal stromal cells (MSC) injection, and extracorporeal photopheresis (ECP) as the most promising or with a benefit/risk balance that favors their prescription at this stage. The workshop also highlighted the importance of research aimed at identifying markers or score calculations that guide toward a risk-adapted approach as early as possible. To date, aside from calprotectin, no marker or score is routinely used, but all are the subject of intense research. Finally, measures associated with specific treatment remain crucial, and new developments in dietary contributions, infection prophylaxis, and tissue regeneration are also addressed.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The transversal specialized formation in oncology for medical gynecology residents: A five-year review]. [妇科住院医师肿瘤横向专科形成：五年回顾]。

IF 0.8

Bulletin du cancer Pub Date : 2025-09-05 DOI: 10.1016/j.bulcan.2025.06.013

Rayan Kabirian, Christine Rousset-Jablonski, Martin Duval, Yazid Belkacemi, Laurent Zelek, Rosine Guimbaud, Charlotte Sonigo, Sophie Catteau-Jonard, Fabien Reyal, Florence Coussy, Anne-Sophie Hamy

{"title":"[The transversal specialized formation in oncology for medical gynecology residents: A five-year review].","authors":"Rayan Kabirian, Christine Rousset-Jablonski, Martin Duval, Yazid Belkacemi, Laurent Zelek, Rosine Guimbaud, Charlotte Sonigo, Sophie Catteau-Jonard, Fabien Reyal, Florence Coussy, Anne-Sophie Hamy","doi":"10.1016/j.bulcan.2025.06.013","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.06.013","url":null,"abstract":"Introduction: The transversal specialized formation (TSF) in oncology has been enabling non-oncologist physicians to acquire oncology skills for five years. This study aims to assess the TSF for medical gynecology residents.Materials and methods: A 23-item questionnaire was sent to physicians from the specialized medical degree (SMD) in medical gynecology who completed the TSF between 2020 and 2023. The data were analyzed using Student's t-tests, Fischer tests, and Chi2 tests.Results: Of the 22 residents identified, 20 (90.9%) responded to the questionnaire. Nine residents (40.9%) were from the Paris region. The reasons for undertaking the TSF included interest in gynecological and breast cancers (81.8%), clinical richness (50.0%), and scientific dynamism (50.0%). Of the 11 respondents who had completed the SMD or had a defined post-residency project, all reported working in a hospital setting. The main activity was gyneco-oncology (n=6, 55.0%), including sexology, monitoring at-risk women, post-cancer care, and medical oncology (n=5, 45.0%). The average satisfaction with the TSF was 7.2/10, with no significant regional difference (P=0.62). Suggested areas for improvement included harmonizing theoretical courses, offering specialized internships in gynecological oncology, and providing mentorship.Discussion: Five years after its implementation, medical gynecologists are satisfied with the TSF in oncology. The main requests are for strengthening national courses and expanding the range of internships, all focused on the original specialty.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0